A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Completed · Phase 2

Conditions studied: HIV Infections

In brief

To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.

Key facts

Study ID

NCT00002190

Run by

Hoffmann-La Roche

People needed

30

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV antibody positive.
• CD4 count >= 150 and <= 500 cells/mm3.

You may not qualify if…

• Prior Medication:
• Excluded:
• Prior antiretroviral therapy.
• Prior protease inhibitor therapy.

Where it is running

• Davies Med Ctr / c/o HIV Institute — San Francisco, California, United States
• Pacific Oaks Med Group / Rsch & Scientific Investigation — Sherman Oaks, California, United States
• Columbia Presbyterian Med Ctr — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.